# A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis

> **NCT04047771** · PHASE1 · TERMINATED · sponsor: **Sichuan Clover Biopharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Peritoneal Carcinomatosis

## Interventions

- **DRUG:** SCB-313

## Key facts

- **NCT ID:** NCT04047771
- **Lead sponsor:** Sichuan Clover Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-10
- **Primary completion:** 2022-05-05
- **Final completion:** 2022-05-05
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** terminated
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047771, "A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04047771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*